AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Novartis AG Director's Dealing 2015

Jun 12, 2015

940_dirs_2015-06-12_680b5743-3065-4fe3-9813-8691e8b9795d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tokai Pharmaceuticals Inc (TKAI)
CIK: 0001404281
Period of Report: 2015-06-11

Reporting Person: Novartis Bioventures Ltd (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-06-11	Common Stock	S	27875	$14.20	Disposed	4567312	Direct

Footnotes

F1: These shares are directly owned by Novartis BioVentures Ltd. Novartis BioVentures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.